The Quantum Promise Revisited

Dr. Sarah Kim gets asked the question at conferences, at family dinners, and once by a taxi driver in Boston who recognized the logo on her conference badge. The question is always some version of the same one: will quantum computing cure Alzheimer’s?

She is 42, a computational chemist at a major pharmaceutical company, and she has a precise answer: no. She is then asked whether quantum computing will change how drugs for Alzheimer’s are discovered. Her answer to that is also precise, and more interesting.

Sarah does not work on a drug. She works on the simulation infrastructure that will identify drug candidates faster, more accurately, and with better predicted safety profiles than classical computing can manage. She cannot name the drug her work will help produce. She can show you the simulation accuracy improving, quarter by quarter, in her specific target class. She finds this sufficient. The piece that follows is the longer version of her two precise answers.

What Quantum Simulation Does

#

The explanation requires no physics degree. Classical computers simulate molecular behavior by approximating. They break the problem into pieces small enough to calculate and then reassemble the answers. For small molecules, the approximations are good enough. A drug candidate with 50 atoms can be simulated with confidence on classical hardware. The predictions about how it will bind to a receptor, how it will be metabolized, and what side effects it might produce are reliable enough to inform the decision about whether to take it into human trials.

For the protein complexes involved in Alzheimer’s pathology, the approximations accumulate error. Amyloid oligomers, tau filaments, and the receptor interactions that drugs need to target involve hundreds of thousands of atoms in configurations where the behavior of each atom affects every other. Classical approximations lose accuracy as the system grows. The predictions become less reliable. The drug candidates that look promising in simulation fail in human trials because the simulation was not accurate enough to predict the failure.

Quantum simulation represents these systems using the same quantum mechanical mathematics that governs the actual molecular behavior. The simulation is not an approximation of the physics. It is the physics, computed directly. For the protein complexes that matter in Alzheimer’s drug discovery, this difference in simulation fidelity translates to a difference in prediction accuracy that the pharmaceutical industry has been waiting decades to achieve.

The Attrition Problem

#

More than 90 percent of drug candidates that enter human clinical trials fail. This is the central inefficiency of pharmaceutical development, and it is the problem that quantum computing addresses most directly.

Most of this failure is not because the biology was wrong. Researchers correctly identify the target. They correctly hypothesize the mechanism. What goes wrong is the translation from hypothesis to molecule: the drug candidate that the simulation predicted would bind effectively to the target does not bind as predicted in the living system. Or it binds as predicted but produces off-target effects the simulation did not foresee. Or it is metabolized in ways the simulation did not model.

Each failed Phase III trial represents roughly a billion dollars and a decade of work. The patients who enrolled received either a drug that did not work or a placebo. The families who waited received neither the treatment nor the answer they were hoping for. The attrition rate is not an abstract number. It is Robert Cheng’s one-in-three chance of receiving placebo in a trial that may fail entirely.

A quantum simulation that correctly predicts which candidates will fail before they enter human trials reduces the cost and time of drug development by improving the quality of what enters trials. Fewer failures means faster progress to the candidates that work. This is what Sarah Kim is building. Not a drug. A filter that makes the drug discovery system more efficient.

What AlphaFold Changed and What It Did Not

#

AlphaFold, developed by DeepMind, solved the protein folding prediction problem in 2020 using classical AI, not quantum computing. Given a protein’s amino acid sequence, AlphaFold can predict its three-dimensional structure with remarkable accuracy. This was a genuine scientific landmark. It was achieved with classical machine learning running on classical hardware.

What AlphaFold did not solve is the problem Sarah works on. Predicting how a protein folds is different from predicting how it behaves. A protein’s static structure tells you its shape. It does not tell you how that shape changes when another molecule binds to it, how it interacts with other proteins in a cellular environment, or how a drug candidate alters its conformational dynamics over time. These dynamic questions require simulation of molecular behavior at a level of complexity where classical computing loses accuracy and quantum computing gains it.

The distinction matters for this piece because it prevents a common confusion. AlphaFold did not make quantum computing unnecessary for drug discovery. It solved one problem (structure prediction) brilliantly and left the harder problems (dynamic behavior, multi-protein interaction, drug-receptor modeling) for the infrastructure Sarah is building.

The Polypharmacy Application

#

The most near-term practical application of quantum simulation for the people this publication serves may not be a new drug. It may be a better understanding of the drugs they already take.

The polypharmacy problem from Series 1 of this publication: fourteen medications, each with its own interaction profile, their pairwise interactions partially characterized by classical pharmacology databases, their three-way and four-way interactions largely unknown. Classical pharmacology can characterize pairwise interactions through empirical testing. It cannot characterize the combinatorial space of fourteen medications taken simultaneously. The number of possible interactions exceeds what empirical testing can cover in a reasonable timeframe.

Quantum simulation of multi-drug interaction chemistry at sufficient complexity to identify previously unknown dangerous combinations is closer to practical application than a new drug. The molecular systems involved are smaller than protein-receptor complexes. The simulation requirements are less demanding. The payoff is immediate: a patient whose AI health companion can check not just the two-drug interaction database but the full combinatorial interaction profile of every medication they take simultaneously.

This application is in development at several pharmaceutical companies and academic centers. Sarah’s team is not working on it directly, but she follows the progress. She estimates practical clinical application within three to five years. For the person taking fourteen medications, this timeline matters more than the drug discovery timeline.

The Honest Timeline

#

Sarah’s timeline, given without hedging:

Quantum-assisted drug candidate identification producing compounds ready for human trials: within five years for specific, well-characterized targets. This means the quantum simulation has identified a candidate that classical methods would have missed or taken years longer to find, and that candidate has passed preclinical safety and efficacy assessment.

Phase I trials for quantum-discovered candidates: five to ten years from now. Phase I trials test safety in small numbers of healthy volunteers. They are the first step in the decade-long process that ends with an approved drug.

An approved drug with quantum-assisted discovery in its lineage: a decade or more. The drug development process from Phase I to approval averages ten to fifteen years. Quantum computing shortens the preclinical phase. It does not shorten the clinical trial phase, which is governed by biology, not computation.

A quantum-derived drug available to Robert Cheng or his grandchildren: Sarah pauses when asked this. Robert’s timeline is shorter than the drug development timeline. His grandchildren’s is not. She says the grandchildren are the more honest answer.

Why She Stays

#

Sarah cannot see the drug she is helping to make. She can see the simulation accuracy improving quarterly in her target class. She can see candidate quality improving in the programs where quantum-assisted discovery has been applied: fewer candidates entering trials, a higher fraction advancing through Phase I, better predicted safety profiles matching observed safety data. The attrition rate is starting to bend in her corner of the field.

She is working on infrastructure. The word sounds bureaucratic. It is not. The researchers who eventually find the drug that slows or stops Alzheimer’s will use tools that Sarah’s generation built. The simulation platforms. The interaction models. The prediction algorithms validated against clinical outcomes. Infrastructure work is the work that does not carry your name on the result. Sarah finds this acceptable. She has a two-year-old daughter. The timeline makes sense to her in a way it does not need to make sense to anyone else.

What It Means Today

#

Quantum computing will not produce a treatment you can take in the next five years. It will improve the drug discovery pipeline that produces the drugs described in 15.01 and every drug that follows. The improvement is real and measurable in the preclinical programs where it has been applied.

Following the progress is worth doing. The reader who wants to track the field can watch for two specific developments: the first public disclosure of a drug candidate identified through quantum-assisted simulation entering human trials, and the first clinical validation of quantum-simulated drug interaction predictions against empirical outcomes. Both are expected within the next three to five years. Both will be reported in publications accessible to a general reader.

Acting on it today means something specific. The research funding that supports quantum computing in drug discovery comes from federal science budgets, pharmaceutical company R&D investment, and academic research grants. The regulatory environment that governs how quantum-assisted discoveries enter clinical trials has not yet been tested. The clinical trial infrastructure that will eventually test quantum-discovered candidates requires sustained enrollment, which requires public trust in the trial process. Each of these is something a citizen can support.

Sarah’s two precise answers remain the frame. Will quantum computing cure Alzheimer’s? No. Will it change how we find the drugs? Yes. The timeline is long. The work is real. The infrastructure is being built.